Replies to post #48257 on Biotech Values

[DewDiligence]

VRTX / IDIX / VPHM / ITMN – I thought the most interesting tidbit from the recent VRTX webcasts was that VRTX thinks the benefit of ribavirin is mainly on the front end of treatment. This is exactly the opposite of the conventional wisdom that ribavirin has little effect in lowering early viral load and is helpful mainly in suppressing relapses.